The new antimicrobials: A review and assessment for formulary consideration

Formulary

Volumn 32, Issue 3, 1997, Pages 232-250

  Flores, Patricia A ^a   Longworth, David L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFTAZIDIME; CEFTIBUTEN; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; DALFOPRISTIN; DIRITHROMYCIN; ERYTHROMYCIN; FOSFOMYCIN; FOSFOMYCIN TROMETAMOL; LEVOFLOXACIN; LEVOQUIN; MACROLIDE; MEROPENEM; MEZLOCILLIN; OFLOXACIN; PIPERACILLIN; QUINUPRISTIN; SPARFLOXACIN; STREPTOGRAMIN DERIVATIVE; UNCLASSIFIED DRUG;

BACTERIAL MENINGITIS; BRONCHITIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG COST; DRUG ELIMINATION; DRUG MECHANISM; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARING LOSS; HUMAN; INFLAMMATION; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; OTITIS MEDIA; PNEUMONIA; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SEIZURE; SKIN INFECTION; URINARY TRACT INFECTION;

EID: 0030946539     PISSN: 00986909     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious diseases mortality in the United States. JAMA 1996; 275:189-93.
2. Edelstein H, Chirurgi V, Oster S, et al. A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia. J Antimicrob Chemother 1991;28:569-75.
3. Hoepelman AI, Kieft H, Aoun M, et al. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections. J Antimicrob Chemother 1993;32(Suppl B):175-86.
4. Holloway WJ, Palmer D. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections. Am J Med 1996;100(Suppl 6A): 52S-59S.
5. Léophonte P, Bertrand A, Nouvet G, et al. A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother 1993;32(Suppl B):165-73.
6. McCabe R, Chirurgi V, Farkas SA, et al. A new therapeutic option for the treatment of pneumonia. Am J Med 1996; 100(Suppl 6A):60S-67S.
7. Yellin AE, Berne TV, Appleman MD, et al. A randomized study of cefepime versus the combination of gentamicin and mezlocillin as an adjunct to surgical treatment in patients with acute cholecystitis. Surg Gynecol Obstet 1993;177 (Suppl):23-9.
8. Thompson JE Jr, Bennion RS, Roettger R, et al. Cefepime for infections of the biliary tract. Surg Gynecol Obstet 1993; 177(Suppl):30-4.
9. Berne TV, Yellin AE, Appleman MD, et al. A clinical comparison of cefepime and metronidazole versus gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis. Surg Gynecol Obstet 1993; 177(Suppl):18-22.
10. Gentry LO, Rodriguez-Gomez G. Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects. Antimicrob Agents Chemother 1991;35: 2371-4.
11. Sharifi R, Geckler R, Childs S. Treatment of urinary tract infections: Selecting an appropriate broad-spectrum antibiotic for nosocomial infections. Am J Med 1996;100(Suppl 6A):76S-82S.
12. Schwartz R, Das-Young LR, Ramirez-Ronda C, Frank E. Current and future management of serious skin and skin-structure infections. Am J Med 1996;100 (Suppl 6A):90S-95S.
13. Newton ER, Yeomans ER, Pastorek JG, et al. Randomized comparative study of cefepime and cefotaxime in the treatment of acute obstetric and gynaecological infections. J Antimicrob Chemother 1993;32(Suppl B):195-204.
14. Ramphal R, Gucalp R, Rotstein C, et al. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996;100 (Suppl 6A):83S-89S.
15. Sáez-Llorens X, Castaño E, García R, et al. Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Antimicrob Agents Chemother 1995;39:937-40.
16. Kammer RB, Ress R. Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infections. Diagn Microbiol Infect Dis 1991;14:101-5.
17. Sader HS, Jones RN, Washington JA, et al. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers. Diagn Microbiol Infect Dis 1993;17:143-50.
18. Wiseman LR, Balfour JA. Ceftibuten: A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1994;47:784-808.
19. Perrotta R, McCabe R, Rumans L, Nolen T. Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of acute bacterial bronchitis. Infect Dis Clin Pract 1994;3:270-6.
20. Chirurgi VA, Edelstein H, Oster SE, et al. Ceftibuten versus cefaclor for the treatment of bronchitis. J Antimicrob Chemother 1991;28:577-80.
21. Blumer JL, McLinn SE, DeAbate A, et al. Multinational multicenter controlled trial comparing ceftibuten with cefaclor for the treatment of acute otitis media. Pediatr Infect Dis J 1995;14(Suppl 7):S115-20.
22. McLinn SE, McCarthy JM, Perrotta R, et al. Multicenter controlled trial comparing ceftibuten with amoxicillin/clavulanate in the empiric treatment of acute otitis media. Pediatr Infect Dis J 1995;14 (Suppl 7):S108-14.
23. Pichichero ME, McLinn SE, Gooch WM III, et al. Ceftibuten vs penicillin V in group A beta-hemolytic streptococcal pharyngitis. Pediatr Infect Dis J 1995;14 (Suppl 7):S102-7.
24. Professional Information Brochure, Cedax. Schering Corporation, Kenilworth, NJ, October 1996.
25. DeAbate CA, Perrotta RJ, Dennington ML, Ziering RM. The efficacy and safety of once-daily ceftibuten compared with co-amoxiclav in the treatment of acute bacterial sinusitis. J Chemother 1992;4: 358-63.
26. Prado D, López E, Liu H, et al. Ceftibuten and trimethoprim-sufamethoxazole for treatment of Shigella and enteroinvasive Escherichia coli disease. Pediatr Infect Dis J 1992;11:644-7.
27. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem: A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995;50:73-101.
28. Professional Information Brochure, Merrem. Zeneca Pharmaceuticals, Wilmington, DE, July 1996.
29. Satake S, Yoneyama H, Nakae T. Role of OmpD2 and chromosomal beta-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 1991;28:199-207.
30. Brismar B, Malmborg AS, Tunevall G, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1995;35:139-48.
31. Kanellakopoulou K, Giamarellou H, Papadothomakos P, et al. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 1993;12:449-53.
32. Geroulanos SJ and the Meropenem Study Group. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. J Antimicrob Chemother 1995;36(Suppl A):191-205.
33. Lopez E and Meropenem Study Group. Meropenem versus cefotaxime or ceftriaxone for bacterial meningitis. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 17 to 20, 1993; New Orleans (abstract 638).
34. Schmutzhard E, Williams KJ, Vukmirovits G, et al. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. J Antimicrob Chemother 1995;36(Suppl A);85-97.
35. Sieger B, Geckler R. A comparison of meropenem and ceftazidime plus tobramycin in the treatment of hospital-acquired lower respiratory infections. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 17 to 20, 1993; New Orleans (abstract 640).
36. Byrne S, Maddison J, Connor P, et al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. J Antimicrob Chemother 1995;36(Suppl A):135-43.
37. Nichols RL, Smith JW, Geckler RW, Wilson SE. Meropenem versus imipenem/ cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995;88:397-404.
38. Kumazawa J, Matsumoto T, Masatoshi T, et al. Clinical evaluation of meropenem for the treatment of complicated urinary tract infections - a double-blind controlled study using imipenem/cilastatin. Nishinippon Hinyokika 1992;54:954-69.
39. Solberg CO, Sjursen H. Safety and efficacy of meropenem in patients with septicaemia: A randomised comparison with ceftazidime, alone or combined with amikacin. J Antimicrob Chemother 1995;36(Suppl A):157-66.
40. Patel JB, Giles RE. Meropenem. Evidence of lack of proconvulsive tendency in mice. J Antimicrob Chemother 1989;24(Suppl A):307-9.
41. Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: International clinical experience based on the first 3,125 patients treated with meropenem. J Antimicrob Chemother 1995;36(Suppl A):207-23.
42. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996;335:392-8.
43. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: Rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996;335:377-83.
44. Hosie J, Quinn P, Smits P, Sides G. A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother 1995;36: 173-83.
45. Caron F, Gold HS, Wennersten CB, et al. Role of growth phase and erythromycin susceptibility on the bactericidal effect of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium. Presented at the International Conference on Macrolides, Azalides, and Streptogramins; January 26, 1996; Lisbon, Portugal.
46. Bernard E, Bensoussan M, Bensoussan F, et al. Pharmacokinetics and suction blister fluid penetration of a semisynthetic injectable streptogramin RP 59500 (RP 57669/RP 54476). Eur J Clin Microbiol Infect Dis 1994;13:768-71.
47. Etienne SD, Montay G, Leliboux A, et al. A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. J Antimicrob Chemother 1992;30(Suppl A):123-31.
48. Griswold MW, Lomaestro BM, Briceland LL. Quinupristin-dalfopristin (RP 59500): An injectable streptogramin combination. Am J Health-Syst Pharm 1996;53:2045-53.
49. Lynn WA, Clutterbuck E, Want S, et al. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium quinupristin/dalfopristin (letter). Lancet 1994;344:1025-6.